RxDoctor Payments Data

Jason Smotherman, MD

Urology · Tucson, AZNPI 1457315301

Payments from drug & device makers

$1,010in general payments, 2019–2025

Across 20 payments — averaging $50.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$353
  • Procept Biorobotics Corporation$217
  • Teleflex LLC$124
  • Intuitive Surgical$99
  • Bayer$75
  • Boston Scientific$53
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$85485%
  • Education$15515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,010 in reported general payments places this provider in the 25th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$194,524
Medicare patients
446
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron201$148,917
MyrbetriqMirabegron156$127,564
EliquisApixaban52$33,644
Finasteride767$9,425
Tamsulosin Hcl768$9,152
XareltoRivaroxaban13$8,405
Solifenacin Succinate131$5,486
Methenamine Hippurate90$4,639
Tolterodine Tartrate ErTolterodine Tartrate46$4,440
Estradiol28$3,182
Testosterone23$1,846
Bicalutamide35$1,498
Dutasteride35$1,303
Potassium Citrate ErPotassium Citrate16$1,187
Oxybutynin Chloride ErOxybutynin Chloride146$1,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$353$127,564156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 269 urology providers in Arizona.

Other urology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →